The pharmacogenetic of cyclosporine in Tunisian renal transplantation.

Authors

Amani Abderahmene, Amira Moussa, Wissal Sahtout, Azzabi Awatif, Meriam Ammar, Dorra Amor, Saoussen Chouchene, Dorsaf Zellama, Ali Bouslama, Asma Omezzine

Published in

Pharmacogenomics. Pages 1-8. Aug 15, 2026. Epub Aug 15, 2026.

Abstract

Our study is the first study, in Tunisia, to investigate the effect of SNPs in CYP3A5, CYP3A4, ABCB1, and POR genes on the response to cyclosporine (CsA).
In a retrospective study, a total of 78 renal transplant patients receiving CsA and mycophenolate mofetil (MMF) were recruited. Genotyping was performed using PROFLEX-PCR followed by RFLP.
We found a significant lower C0/D CsA in patients with at least one CYP3A4*1B allele compared to the wild type (p = 0.001). We found a statistically significant increased risk of acute and chronic rejection associated with carrying CYP3A5*1/*1 or *1/*3 compared to the CYP3A5*3/*3 and of carrying CYP3A*51B/*1B or *1/*1B compared to the CYP3A4*1/*1 (p = 0.001). The occurrence of leukopenia was significantly decreased in patients with at least one CYP3A4*1B allele (p = 0.01). and the occurrence of diarrhea was significantly increased in patients carrying the variant allele of ABCB1-3435C>T (p = 0.005).
Our results support the usefulness of CsA pharmacokinetics tests in prekidney transplant assessments.

PMID:
42603263
Bibliographic data and abstract were imported from PubMed on 16 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.